細胞名稱：人肺癌細胞NCI-H1755
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研用途2類
培養(yǎng)體系：1640+10%胎牛血清（Gibco）+1%雙抗（Hyclone）
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人肺癌細胞NCI-H1755細胞系取自高加索人種，女性，65歲。該患者有吸煙史。
注釋：Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:KuDOS 95 cell line panel.
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:Deep proteome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
STR信息
Amelogenin:X
CSF1PO:12
D13S317:10,12
D16S539:11,12
D5S818:11,12
D7S820:12
F13A01:4,6
F13B:8,10
FESFPS:11
LPL:12
TH01:7
TPOX:8
vWA:18
參考文獻
PubMed=1311061
Mitsudomi T.,Steinberg S.M.,Nau M.M.,Carbone D.,D'Amico D.,Bodner S.,Oie H.K.,Linnoila R.I.,Mulshine J.L.,Minna J.D.,Gazdar A.F.
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Oncogene 7:171-180(1992)
PubMed=8806092;DOI=10.1002/jcb.240630505
Phelps R.M.,Johnson B.E.,Ihde D.C.,Gazdar A.F.,Carbone D.P.,McClintock P.R.,Linnoila R.I.,Matthews M.J.,Bunn P.A.Jr.,Carney D.N.,Minna J.D.,Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J.Cell.Biochem.63 Suppl.24:32-91(1996)
PubMed=11030152;DOI=10.1038/sj.onc.1203815
Modi S.,Kubo A.,Oie H.,Coxon A.B.,Rehmatulla A.,Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)
PubMed=12068308;DOI=10.1038/nature00766
Davies H.,Bignell G.R.,Cox C.,Stephens P.,Edkins S.,Clegg S.,Teague J.W.,Woffendin H.,Garnett M.J.,Bottomley W.,Davis N.,Dicks E.,Ewing R.,Floyd Y.,Gray K.,Hall S.,Hawes R.,Hughes J.,Kosmidou V.,Menzies A.,Mould C.,Parker A.,Stevens C.,Watt S.,Hooper S.,Wilson R.,Jayatilake H.,Gusterson B.A.,Cooper C.,Shipley J.M.,Hargrave D.,Pritchard-Jones K.,Maitland N.J.,Chenevix-Trench G.,Riggins G.J.,Bigner D.D.,Palmieri G.,Cossu A.,Flanagan A.M.,Nicholson A.,Ho J.W.C.,Leung S.Y.,Yuen S.T.,Weber B.L.,Seigler H.F.,Darrow T.L.,Paterson H.,Marais R.,Marshall C.J.,Wooster R.,Stratton M.R.,Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)
PubMed=20164919;DOI=10.1038/nature08768
Bignell G.R.,Greenman C.D.,Davies H.,Butler A.P.,Edkins S.,Andrews J.M.,Buck G.,Chen L.,Beare D.,Latimer C.,Widaa S.,Hinton J.,Fahey C.,Fu B.,Swamy S.,Dalgliesh G.L.,Teh B.T.,Deloukas P.,Yang F.,Campbell P.J.,Futreal P.A.,Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515;DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M.,Mohapatra G.,Rivera M.N.,Winokur D.,Greninger P.,Nitta M.,Sadow P.M.,Sooriyakumar G.,Brannigan B.W.,Ulman M.J.,Perera R.M.,Wang R.,Tam A.,Ma X.-J.,Erlander M.,Sgroi D.C.,Rocco J.W.,Lingen M.W.,Cohen E.E.W.,Louis D.N.,Settleman J.,Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res.70:2158-2164(2010)
PubMed=22460905;DOI=10.1038/nature11003
Barretina J.G.,Caponigro G.,Stransky N.,Venkatesan K.,Margolin A.A.,Kim S.,Wilson C.J.,Lehar J.,Kryukov G.V.,Sonkin D.,Reddy A.,Liu M.,Murray L.,Berger M.F.,Monahan J.E.,Morais P.,Meltzer J.,Korejwa A.,Jane-Valbuena J.,Mapa F.A.,Thibault J.,Bric-Furlong E.,Raman P.,Shipway A.,Engels I.H.,Cheng J.,Yu G.K.,Yu J.,Aspesi P.Jr.,de Silva M.,Jagtap K.,Jones M.D.,Wang L.,Hatton C.,Palescandolo E.,Gupta S.,Mahan S.,Sougnez C.,Onofrio R.C.,Liefeld T.,MacConaill L.E.,Winckler W.,Reich M.,Li N.,Mesirov J.P.,Gabriel S.B.,Getz G.,Ardlie K.,Chan V.,Myer V.E.,Weber B.L.,Porter J.,Warmuth M.,Finan P.,Harris J.L.,Meyerson M.,Golub T.R.,Morrissey M.P.,Sellers W.R.,Schlegel R.,Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=24805778;DOI=10.14348/molcells.2014.0035
Min H.,Han D.-H.,Kim Y.-W.,Cho J.-Y.,Jin J.-H.,Kim Y.-S.
Label-free quantitative proteomics and N-terminal analysis of human metastatic lung cancer cells.
Mol.Cells 37:457-466(2014)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=29444439;DOI=10.1016/j.celrep.2018.01.051
Yuan T.L.,Amzallag A.,Bagni R.,Yi M.,Afghani S.,Burgan W.,Fer N.,Strathern L.A.,Powell K.,Smith B.,Waters A.M.,Drubin D.,Thomson T.,Liao R.,Greninger P.,Stein G.T.,Murchie E.,Cortez E.,Egan R.K.,Procter L.,Bess M.,Cheng K.T.,Lee C.-S.,Lee L.C.,Fellmann C.,Stephens R.,Luo J.,Lowe S.W.,Benes C.H.,McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep.22:1889-1902(2018)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
驗收細胞注意事項
1、收到人肺癌細胞NCI-H1755細胞，請查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請盡快聯(lián)系。
2、收到人肺癌細胞NCI-H1755細胞，如包裝完好，請在顯微鏡下觀察細胞。,由于運輸過程中的問題，細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現(xiàn)細胞懸浮的情況，出現(xiàn)此狀態(tài)時，請不要打開細胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜止3-5小時左右，讓細胞先穩(wěn)定下，再于顯微鏡下觀察，此時多數(shù)細胞會重新貼附于瓶壁。如細胞仍不能貼壁，請用臺盼藍染色法鑒定細胞活力，如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。
3、收到人肺癌細胞NCI-H1755細胞后，請鏡下觀察細胞，用恰當方式處理細胞。若懸浮的細胞較多，請離心收集細胞，接種到一個新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進口胎牛血清。剛接到細胞，若細胞不多時血清濃度可以加到15％去培養(yǎng)。若細胞迏到80%左右，血清濃度還是在10％。
4、收到人肺癌細胞NCI-H1755細胞時如無異常情況，請在顯微鏡下觀察細胞密度，如為貼壁細胞，未超過80%匯合度時，將培養(yǎng)瓶中培養(yǎng)基吸出，留下5-10ML培養(yǎng)基繼續(xù)培養(yǎng)：超過80%匯合度時，請按細胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細胞，吸出培養(yǎng)液，1000轉(zhuǎn)/分鐘離心3分鐘，吸出上清，管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶。
5、將培養(yǎng)瓶置于37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于4℃冰箱，以備不時之需。
6、24小時后，人肺癌細胞NCI-H1755細胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加3-5ml（以能覆蓋細胞生長面為準）PBS或Hanks’液洗滌后棄去。加0.5-1ml 0.25%含EDTA的胰酶消化，消化時間以具體細胞為準，一般1-3分鐘，不超過5分鐘?？梢苑湃?7℃培養(yǎng)箱消化。輕輕晃動瓶壁，見細胞脫落下來，加入3-5ml培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞，使之完全脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細胞數(shù)量決定分瓶數(shù)，一般一傳二，如細胞量多可一傳三，有些細胞不易傳得過稀，有些生長較快的細胞則可以多傳幾瓶，以具體細胞和經(jīng)驗為準。（懸浮細胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。
7、貼壁細胞，懸浮細胞。嚴格無菌操作。換液時，換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液，37℃，5%CO2培養(yǎng)。
特別提醒：原瓶中培養(yǎng)基不宜繼續(xù)使用，請更換新鮮培養(yǎng)基培養(yǎng)。
